Rapport Therapeutics, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Rapport Therapeutics files an amendment to its S-1 registration statement, including amended bylaws and details regarding its upcoming IPO and Nasdaq listing.
NASDAQ
Rapport Therapeutics, a clinical-stage biopharmaceutical company, has filed for an initial public offering to fund the development of its small molecule medicines for central nervous system disorders.